Abstract
Schizophrenia is a mental disease that mainly affects young individuals (15 to 35 years old) but its etiology remains largely undefined. Recently, accumulating evidence indicated that demyelination and/or dysfunction of oligodendrocytes is an important feature of its pathogenesis. We hypothesized that the vulnerability of young individuals to demyelination may contribute to the onset of schizophrenia. In the present study, three different age cohorts of mice, i.e. juvenile (3 weeks), young-adult (6 weeks) and middle-aged (8 months), were subjected to a 6-week diet containing 0.2% cuprizone (CPZ) to create an animal model of acute demyelination. Then, age-related vulnerability to CPZ-induced demyelination, behavioral outcomes, and myelination-related molecular biological changes were assessed. We demonstrated: (1) CPZ treatment led to more severe demyelination in juvenile and young-adult mice than in middle-aged mice in the corpus callosum, a region closely associated with the pathophysiology of schizophrenia; (2) the higher levels of demyelination in juvenile and young-adult mice were correlated with a greater reduction of myelin basic protein, more loss of CC-1-positive mature oligodendrocytes, and higher levels of astrocyte activation; and (3) CPZ treatment resulted in a more prominent exploratory behavior deficit in juvenile and young-adult mice than in middle-aged mice. Together, our data demonstrate an age-related vulnerability to demyelination with a concurrent behavioral deficit, providing supporting evidence for better understanding the susceptibility of the young to the onset of schizophrenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995, 346: 552–557.
Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Kamino K, et al. The KCNH2 gene is associated with neurocognition and the risk of schizophrenia. World J Biol Psychiatry 2013, 14(2): 114–120.
Goldberg X, Fatjo-Vilas M, Penades R, Miret S, Munoz MJ, Vossen H, et al. Neurodevelopmental liability to schizophrenia: The complex mediating role of age at onset and premorbid adjustment. Schizophr Res 2011, 133(1–3): 143–149.
Bhugra D. The global prevalence of schizophrenia. PLoS Med 2005, 2: e151; quiz e175.
Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull 2011, 37: 504–513.
Naqvi I, Murtaza M, Nazir MR, Naqvi HA. Gender difference in age at onset of schizophrenia: a cross sectional study from Pakistan. J Pak Med Assoc 2010, 60: 886–889.
Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 2011, 93: 13–24.
Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P, et al. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res 2010, 120: 150–158.
Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002, 22: 2451–2459.
Minami T, Nobuhara K, Okugawa G, Takase K, Yoshida T, Sawada S, et al. Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. Neuropsychobiology 2003, 47: 141–145.
Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005, 26: 1109–1118.
Buchsbaum MS, Schoenknecht P, Torosjan Y, Newmark R, Chu KW, Mitelman S, et al. Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. Ann Gen Psychiatry 2006, 5: 19.
Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci U S A 2006, 103: 7482–7487.
Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 2003, 8: 811–820.
Stewart DG, Davis KL. Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. Int Rev Neurobiol 2004, 59: 381–424.
Xu H, Yang HJ, Zhang Y, Clough R, Browning R, Li XM. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behav Neurosci 2009, 123: 418–429.
Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008, 13: 697–708.
Yang HJ, Wang H, Zhang Y, Xiao L, Clough RW, Browning R, et al. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia. Brain Res 2009, 1270: 121–130.
Herring NR, Konradi C. Myelin, copper, and the cuprizone model of schizophrenia. Front Biosci 2011, 3: 23–40.
Wang H, Xu H, Niu J, Mei F, Li X, Kong J, et al. Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain. Schizophr Res 2010, 119: 164–174.
Brunet-Gouet E, Decety J. Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res 2006, 148: 75–92.
Enomoto T, Floresco SB. Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33: 668–675.
Zhang Y, Xu H, Jiang W, Xiao L, Yan B, He J, et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res 2008, 106: 182–191.
Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001, 11: 107–116.
Irvine KA, Blakemore WF. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 2006, 175: 69–76.
Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 2003, 13: 329–339.
Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008, 11: 1024–1034.
Ren Y, Wang H, Xiao L. Improving myelin/oligodendrocyterelated dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenia? Int J Neuropsychopharmacol 2012: 1–10.
Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci 2007, 64: 50–65.
Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, et al. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 2009, 1283: 127–138.
Pott F, Gingele S, Clarner T, Dang J, Baumgartner W, Beyer C, et al. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 2009, 1305: 137–149.
Steelman AJ, Thompson JP, Li J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res 2012, 72(1): 32–42.
Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010, 120: 223–236.
Saikali P, Antel JP, Pittet CL, Newcombe J, Arbour N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J Immunol 2010, 185: 5693–5703.
Kim S, Steelman AJ, Zhang Y, Kinney HC, Li J. Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol 2012, 22(1): 41–57.
Kim HJ, Miron VE, Dukala D, Proia RL, Ludwin SK, Traka M, et al. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J 2011, 25: 1509–1518.
Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 2007, 169: 205–213.
Makinodan M, Yamauchi T, Tatsumi K, Okuda H, Takeda T, Kiuchi K, et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33: 978–985.
Hiroi R, Neumaier JF. Differential effects of ovarian steroids on anxiety versus fear as measured by open field test and fear-potentiated startle. Behav Brain Res 2006, 166: 93–100.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wang, H., Li, C., Wang, H. et al. Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. Neurosci. Bull. 29, 251–259 (2013). https://doi.org/10.1007/s12264-013-1323-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-013-1323-1